Actively Recruiting
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Led by Vanderbilt University Medical Center · Updated on 2025-08-14
100
Participants Needed
1
Research Sites
243 weeks
Total Duration
On this page
Sponsors
V
Vanderbilt University Medical Center
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk distance (6MWD) and HRQOL improvement that often exceeds the effect of medications. Prior activity studies required inpatient rehabilitation, which is impractical, hard to sustain, and poorly scalable to a rare disease. The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.
CONDITIONS
Official Title
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 or older
- Diagnosed with idiopathic, heritable, or associated pulmonary arterial hypertension (PAH), or PAH due to simple congenital heart disease such as atrial septal defect
- WHO functional class I to III
- Stable PAH-specific medication regimen for three months prior to enrollment; a single diuretic adjustment in the prior three months is allowed
- Forced vital capacity greater than 65% predicted with no or minimal interstitial lung disease based on imaging review
You will not qualify if you...
- Unable to perform normal activity due to wheelchair or bed bound status, reliance on cane/walker, activity-limiting angina or osteoarthritis, or other limiting condition
- Pregnant
- Diagnosis of PAH other than idiopathic, heritable, or associated forms
- Functional class IV heart failure
- More than two diuretic adjustments in the prior three months
- Preferred physical activities not measurable by activity tracker (e.g., swimming, yoga, ice skating, stair master, bicycling, rollerblading)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
Research Team
A
Alisha Lindsey, RT
CONTACT
E
Evan Brittain, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here